ASX Announcement MAYNE PHARMA REPORTS 2018 HALF YEAR PERFORMANCE
|
|
- Eustace Blankenship
- 6 years ago
- Views:
Transcription
1 23 February 2018 MAYNE PHARMA REPORTS 2018 HALF YEAR PERFORMANCE Revenue of $243.3m, a decrease of 17% on 1HFY17 Adjusted EBITDA of $70.2m, down 36% on 1HFY17 Reported EBITDA of $23.0m, down 82% on 1HFY17 Reported net loss after tax of $174.2m driven by asset impairments, abnormal Doryx returns and stock obsolescence, restructuring expenses and restatement of deferred tax assets and liabilities following the US tax rate change Positive operating cash flow of $48.0m Significantly improved trading in 2QFY18 which has strengthened further into January US generic market appears to be stabilising and competitor disruptions creating opportunities Expanded Specialty Brands team to 120 sales representatives to drive growth of Fabior, Sorilux and Doryx MPC New Greenville manufacturing facility to commence production in the next month, enhancing internal capabilities and improving margins for third party transferred products Business positioned for a stronger second half driven by stabilising generic market, new product launches, expanded dermatology sales team, contract services committed business pipeline and cost benefits from the restructure Commenting on the half year result, Mayne Pharma s CEO, Mr Scott Richards said, While our first half results reflect a challenging generic environment and a disappointing Specialty Brands result, Mayne Pharma continues to have a number of strong performing business segments, products and pipeline opportunities. Metrics Contract Services, Mayne Pharma International, dofetilide capsules, doxycycline hyclate IR tablets and budesonide capsules were key contributors in the half versus the prior corresponding period. The pipeline is expected to drive growth in future periods driven by key launches including generic NuvaRing and our patented formulation of SUBA - Itraconazole as an anti-fungal in the United States. Summary of results 1 Change on pcp $m 1HFY18 1HFY17 pcp $m % Revenue (51.5) (17%) Gross profit (75.3) (44%) GM% 39% 58% EBITDA adjusted (39.7) (36%) EBITDA reported (106.2) (82%) Net income / (loss) - adjusted (43.5) (73%) Net income / (loss) - reported (174.2) 72.7 (256.9) Nm 1. Earnings attributable to members of the Company. 2. Adjustments to EBITDA in 1HFY18 include $17.3m abnormal stock adjustments, $13.3m abnormal Doryx returns, $14.0m restructuring charge and $2.6m to remove HedgePath Pharmaceuticals Inc. (HPPI) losses and the fair value restatement of of HPPI warrants. As foreshadowed at the AGM in November 2017, the Company completed a detailed review of the Company s intangible assets taking into account the current and projected market dynamics. This has resulted in a non-cash (pre-tax) charge of $184m relating largely to the intangible asset Page 1
2 impairment of the acquired Teva portfolio assets. In addition, the reported results have been impacted by a number of abnormal one-off items including $17m of extraordinary stock obsolescence charges and sell through of short dated stock below cost, $13m of abnormal Doryx returns and sample write-offs, and a $14m restructuring charge to reduce the cost base - covering the cancellation of employee loan shares, renegotiation of supply chain contracts and other expense management initiatives. The ongoing restructure of the cost base across FY18 is expected to drive benefits of up to $7m on an annual basis. During the period, the Tax Cuts and Jobs Act was signed into US legislation which resulted in the corporate federal tax rate declining from 35% to 21% from 1 January Reported NPAT has been impacted by a one-off charge to income tax expense of $14m which reflects the restatement of deferred tax assets and liabilities. Adjusting for these one-off items, group revenue would have been down 13% on pcp, gross profit margin would have been 50% and adjusted EBITDA was $70.2m down 36%. The Company remains committed to growing its core business segments by investing in both internal and external product development opportunities. During the half, the Company invested $63m in its facilities and product pipeline with $40m primarily spent on the expansion programs at Greenville and Salisbury, in addition to $23m on research and development. The solid oral dose manufacturing facility in Greenville is almost complete and the Company is in the process of transferring in house 8 acquired Teva products which are currently outsourced. This will increase the economic benefit that flows to Mayne Pharma as well as introduce downstream commercial manufacturing services to Metrics Contract Services. Operating Performance Generic Products Division (GPD) The GPD operating segment s sales were $180.9m, down 19% on 1HFY17 and gross profit was $63.6m. In US dollar terms, sales were US$141m down 16% on pcp and down 5% on 2HFY17. Price deflation pressures have begun to abate with the generic portfolio experiencing low single digit deflation in 1HFY18 versus 2HFY17. Dofetilide remains the largest generic product and grew 19% on pcp to US$33m. Doxycycline, budesonide and carbidopa/levodopa grew strongly, offset by continued competitiveness across the oral contraceptive portfolio. Gross profit margin was impacted by $17m of one-off abnormal stock adjustments including stock obsolescence, writedowns and sell through of short dated stock below cost to mitigate the full obsolescence risk as well as $3m of restructuring costs to improve the cost base. Adjusting for these one-off items, the generic gross profit margin would have been 46%, instead of 35%. The Company is focused on expanding channels to market, extracting cost savings from optimising the supply network, aggressively pursuing new opportunities through launching products, portfolio optimisation and business development activity. Since October 2017, GPD performance has significantly strengthened with 2QFY18 sales up 30% on 1QFY18 and January 2018 sales were up 13% on the monthly average in 2QFY18. Page 2
3 Cost savings from the transfer of acquired Teva products into Greenville, Salisbury or alternate contract manufacturing organisations continue to progress. The Company expects to achieve US$12m of cost savings on an annual basis from these transfers through accessing lower manufacturing costs at the new network of contract manufacturers or gains from overhead recovery throughput benefits across the internal manufacturing network. Metrics Contract Services (MCS) The MCS operating segment s sales were $29.7m, up 6% on 1HFY17 and gross profit was $15.8m, up 2% on pcp. In US dollar terms, MCS sales were up 9% on pcp to US$23m with gross margins of 53%. The opening of the new Greenville commercial manufacturing facility is expected to transition MCS from a project based revenue stream to include a mix of ongoing recurring revenue streams related to commercial manufacturing. MCS supported registration batch manufacture for 3 programs over the half in addition to supporting its first client complete manufacturing process validation for approval and launch of its product in The pipeline of commercial manufacturing opportunities continues to grow, and the Company expects to receive its first commercial manufacturing revenues in the 2HFY18. Specialty Brands Division (SBD) The SBD operating segment s sales were $13.8m and gross profit was $11.6m. These results were negatively impacted by $12.4m of Doryx returns which related to the loss of exclusivity on legacy Doryx 50mg and 200mg tablets in May Excluding Doryx returns, SBD adjusted revenue would have been $26m consistent with pcp and gross margin would have been 91%. The 1QFY18 sales were impacted due to seasonality of acne products through the summer months, a 1 July price rise on Fabior which drove strong sales in June 2017 and heightened loyalty card costs due to a one-off promotion offer. The 2QFY18 adjusted revenues rebounded and grew 49% on the 1QFY18. Towards the end of the half, the Company doubled the sales team to 120 sales representatives and the impact of this investment is yet to be seen in the financial results. In the latest week of prescription data, which measures underlying demand of these products, Doryx MPC, Fabior and Sorilux prescriptions were up 12%, 17% and 86% respectively on the baseline prior to the expansion of the sales team 1. Mayne Pharma International (MPI) The MPI operating segment s sales were $18.8m, up 8% and gross profit was $5.0m, up 31%. Australian sales grew strongly driven by aspirin, itraconazole and injectables and international sales benefited from the renegotiation of supply agreements. Urorec capsules, indicated for the relief of lower urinary tract symptoms associated with benign prostatic hyperplasia in adult men and Monurol granules, used to treat urinary tract infections were launched during the period, also contributing to the growth. 1 Based on IQVIA, weekly TRx as at 9 February 2018 versus baseline prior to expansion of the second sales team in 1QFY18. Page 3
4 Pipeline The Company continues its commitment to advancing its product pipeline. In 1HFY18 research and development spend was $23.2m of which more than 80% was directed towards US generic programs that leverage the Company s drug delivery platform technologies. Mayne Pharma s US development pipeline consists of 30+ products targeting US markets with sales greater than US$5bn 2 of which 13 products are pending approval at the FDA with total market sales of more than US$1bn 2. During the half, the Company received FDA approval for three generic products doxycycline monohydrate capsules, clozapine tablets (50 mg and 200 mg) and amiodarone tablets; filed three products with the FDA and added two products into development. SUBA-Itraconazole In the 2HFY18, the Company expects to submit a New Drug Application to the FDA for SUBA- Itraconazole capsules to treat certain fungal infections and is targeting commercial launch in FY19, through a dedicated infectious disease sales team. SUBA-Itraconazole is a patented formulation which has improved absorption and significantly reduced variability in blood levels achieved compared to Sporanox (the originator formulation). In Australia and Spain, where the product has been available for several years, it has captured more than 30% and 25% market share respectively of itraconazole prescriptions. The US addressable market is expected to be US$200m per annum based on target pricing and the systemic infection patient population. In January 2018, the Company invested a further US$2.4m in HedgePath Pharmaceuticals Inc. (HPPI), a partly owned subsidiary of Mayne Pharma to progress the development of itraconazole as a potential treatment for cancer. HPPI has completed enrolment of its Phase IIb clinical trial in patients with a genetic form of skin cancer called Basal Cell Carcinoma Nevus Syndrome (BCCNS) more commonly known as Gorlin Syndrome and continues to report positive results from its open label trial. In the latest data set they have measured the response of 477 individual target tumours, with 54% exhibiting a 30% or greater reduction in size since dosing began and 28% disappearing completely. Approximately 60% of lesions have continued to respond during ongoing treatment with a duration of response currently exceeding one year. The US addressable market is estimated at US$300m per annum based on an assessment of current healthcare costs to treat this patient population. Mayne Pharma is also exploring broader oncology indications including prostate and ovarian cancer. Net Debt and Cash Flow The Company ended the year with net debt of $303m. Cash on hand at 31 December 2017 was $56m and the Company had borrowings of $359m. The Company achieved positive net operating cash flow after interest, tax, working capital and oneoff items of $48.0m. Significant cash flow items during the period include $39.5m in capital expenditure, $23.2m payments for product development (expensed and capitalised), $17.8m in earn-out payments, $6.8m in net tax payments, $6.9m in net interest and a $8.8m working capital release. 2 IQVIA, MAT sales, Dec 2017 Page 4
5 Outlook With the positive trading momentum over the last three months, the Group is well positioned for a stronger second half, driven by the stabilising generic market, new product launches, increased share penetration of on market products, portfolio optimisation and expanding distribution channels. SBD is poised to benefit from the expansion of the dermatology sales team which was completed in December MCS key performance indicators are trending favourably for growth over the remainder of the financial year with committed business up 30% from twelve months ago. MPI is expected to benefit following the launch of Monurol and Urorec in 1HFY18. With improving cash generation, the Company will continue to invest in both internal and external growth initiatives that can broaden the portfolio, improve profitability and create long-term shareholder value. For further information contact: Nick Freeman Lisa Pendlebury , lisa.pendlebury@maynepharma.com About Mayne Pharma Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide. Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world. Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in formulating complex oral dose forms including highly potent compounds, controlled substances, modified release products and inherently unstable compounds. Page 5
Mayne Pharma Group Limited
Mayne Pharma Group Limited 1HFY18 Results Presentation 23 February 2018 Scott Richards, Chief Executive Officer Nick Freeman, Group Chief Financial Officer 1 Disclaimer The information provided is general
More informationASX Announcement MAYNE PHARMA REPORTS RECORD FY14 RESULT
MAYNE PHARMA REPORTS RECORD FY14 RESULT 27 August 2014, Melbourne Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to release its consolidated results for the year ended 30 June 2014. The Group
More informationFor personal use only
Mayne Pharma Group Limited FY16 Results Presentation 26 August 2016 Scott Richards, Chief Executive Officer Mark Cansdale, Group CFO 1 Disclaimer The information provided is general in nature and is in
More informationMayne Pharma Group Limited
Mayne Pharma Group Limited FY17 Results Presentation 25 August 2017 Scott Richards, Chief Executive Officer Nick Freeman, Group Chief Financial Officer 1 Disclaimer The information provided is general
More informationMayne Pharma Group Limited
Mayne Pharma Group Limited 1HFY19 Results Presentation 22 February 2019 Scott Richards, Chief Executive Officer Nick Freeman, Group Chief Financial Officer 1 Disclaimer The information provided is general
More informationMayne Pharma Group Limited
Mayne Pharma Group Limited HY14 Results Presentation 26 February 2014 Scott Richards, Chief Executive Officer Mark Cansdale, Group CFO Disclaimer The information provided is general in nature and is in
More informationMayne Pharma Group Limited
Mayne Pharma Group Limited 1HFY17 Results Presentation 24 February 2017 Scott Richards, Chief Executive Officer Mark Cansdale, Group CFO 1 Disclaimer The information provided is general in nature and is
More informationMayne Pharma Group Limited
Mayne Pharma Group Limited FY14 Results Presentation 27 August 2014 Scott Richards, Chief Executive Officer Mark Cansdale, Group CFO Disclaimer The information provided is general in nature and is in summary
More informationFriday, 22 February Manager, Company Announcements ASX Limited Level 4 20 Bridge Street SYDNEY NSW Via E-Lodgement.
Friday, 22 February 2019 Manager, Company Announcements ASX Limited Level 4 20 Bridge Street SYDNEY NSW 2000 Via E-Lodgement Dear Sir/Madam Mayne Pharma Group Limited Please find attached the, Directors
More informationFor personal use only
MAYNE PHARMA ANNOUNCES ACQUISITION OF US GENERIC PRODUCT PORTFOLIO FROM TEVA AND ALLERGAN NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES 28 June 2016, Adelaide, South Australia Mayne Pharma Group
More informationAnnual Report maynepharma.com
Annual Report maynepharma.com Business snapshot Direct Commercial presence Indirect presence through distribution partners for current and pipeline products R&D and manufacturing facility Greenville, North
More informationFor personal use only
24 August Manager, Company Announcements ASX Limited Level 4 20 Bridge Street SYDNEY NSW 2000 Via E-Lodgement Dear Sir/Madam Mayne Pharma Group Limited Preliminary Final Report and accompanying announcement
More informationBuilding our tomorrow
Building our tomorrow Annual Report maynepharma.com What s inside Overview 4 About Mayne Pharma 6 FY17 Business Highlights 8 Chairman s Letter 10 Chief Executive Officer s Review 12 Global Leadership Group
More informationThis information should be read in conjunction with Mayne Pharma Group Limited s 2014 Annual Report.
Thursday, 26 February 2015 Manager, Company Announcements ASX Limited Level 4 20 Bridge Street SYDNEY NSW 2000 Via E-Lodgement Dear Sir/Madam Mayne Pharma Group Limited Please find attached the Appendix
More informationFor personal use only
Manager, Company Announcements ASX Limited Level 4 20 Bridge Street SYDNEY NSW 2000 Friday, 25 February 2011 Via E-Lodgement Dear Sir/Madam Mayne Pharma Group Interim Results Please find attached the Appendix
More informationAcrux (ASX: ACR) Annual General Meeting. 10 November, 2016
Acrux (ASX: ACR) Annual General Meeting 10 November, 2016 1 Introduction: Ross Dobinson Non-Executive Chairman 2 Company review: Michael Kotsanis CEO & Managing Director 3 Forward looking statements This
More informationMayne Pharma Group Limited
Mayne Pharma Group Limited Acquisition of LORCET and ESGIC brand franchises 12 February 2014 Important Notice and Disclaimer The following notice and disclaimer applies to this presentation (Presentation)
More informationMarket Release November
Market Release November 23 2017 FINANCIAL RESULTS FOR HALF YEAR ENDED 30 SEPTEMBER 2017 AFT Pharmaceuticals Limited (NZX; AFT, ASX; AFP) today announced its half-year unaudited financial results for the
More informationCover-More Group. UBS Australasia Conference. November 2015
Cover-More Group UBS Australasia Conference November 2015 Executive summary: FY15 overview Cover-More delivered another year of double digit earnings growth, with offshore business growing substantially.
More informationFor personal use only
ASX/Media Release 30 August 2017 Botanix Pharmaceuticals Preliminary Final Report Highlights for the year ending 30 June 2017: Transformed single product company into rapidly growing medical dermatology
More informationAlembic Pharmaceuticals Ltd
Pharmaceuticals Ltd Investor Presentation January-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Nine Months Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual Safe
More informationResults for the fourth quarter and full year Establishing a Specialty Pharma company
Results for the fourth quarter and full year 2011 Establishing a Specialty Pharma company 16 February 2012 Highlights for the fourth quarter and full year 2011 Photocure (OSE: PHO), a Norwegian specialty
More informationAlembic Pharmaceuticals Ltd. Investor Presentation
Alembic Pharmaceuticals Ltd Investor Presentation October-2016 Contents 1. Milestones 2. Quarterly Highlights 3. Half yearly Highlights 4. Business - International - India Branded 5. Strategy 6. Financials
More informationBetter health. Within reach. Every day.
Better health. Within reach. Every day. v Hikma Pharmaceuticals PLC 2018 Interim Results Hikma Pharmaceuticals PLC Group 1H18 financial highlights $989m $214m 21.6% 61.4 $185m Revenue Core 1 operating
More informationFor personal use only
Sirtex Medical Limited 2017 Annual General Meeting Sydney, Australia 24 October 2017 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd 1For personal use only 2017 Annual General Meeting
More informationQ4 and Full Year 2018 Earnings Call
We make healthy possible Q4 and Full Year 2018 Earnings Call Financial Results and Business Update February 28, 2019 Safe Harbor Statement Safe Harbor Statement Certain statements contained herein, regarding
More informationEndo International plc
Endo International plc Q1 2015 Earnings Report May 11, 2015 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private
More informationUDG Healthcare plc Interim Results Presentation FY17. London Stock Exchange, 23 rd May 2017
UDG Healthcare plc Interim Results Presentation FY17 London Stock Exchange, 23 rd May 2017 Forward looking statements This Presentation has been prepared by UDG Healthcare plc and contains certain forward-looking
More informationBusiness Update. USPP Conference Miami. Luis Damasceno Group CFO Michael Williams Group Finance Director & Treasurer January 2019
Business Update USPP Conference Miami Luis Damasceno Group CFO Michael Williams Group Finance Director & Treasurer 23-25 January 2019 www.alsglobal.com IMPORTANT NOTICE AND DISCLAIMER This presentation
More informationQ Earnings Call
We make healthy possible Q3 2018 Earnings Call Financial Results and Business Update November 7, 2018 Safe Harbor Statement & Non-GAAP Financial Measures Safe Harbor Statement Certain statements contained
More informationLonza Ltd Muenchensteinerstrasse 38 CH-4002 Basel, Switzerland
News Release Lonza Reports Strong Momentum with Organic Growth of 8% Sales and 11% CORE EBITDA in H1 2018 Double-Digit Organic Sales Growth for Businesses Along the Healthcare Continuum Outperformance
More informationGoldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO
Goldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO 05.01.2012 Forward Looking Statements This presentation contains both historical and forward-looking statements.
More informationUniversal Biosensors releases FY2017 results - strong revenue growth and cash generation continues
Universal Biosensors Inc. ARBN 121 559 993 1 Corporate Avenue Rowville VIC 3178 Australia Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email info@universalbiosensors.com www.universalbiosensors.com
More informationAlembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd Investor Presentation May-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Annual Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual 7.
More informationAlembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd Investor Presentation July-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Yearly Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual 7.
More informationSOUTHERN CROSS AUSTEREO H1 FY19 INVESTOR PRESENTATION
SOUTHERN CROSS AUSTEREO H1 FY19 INVESTOR PRESENTATION 21st February 2019 1 Disclaimer Summary information The material in this presentation has been prepared by Southern Cross Media Group Limited ABN 91
More informationAcrux (ASX: ACR) 1H FY17 Results February 2017
Acrux (ASX: ACR) 1H FY17 Results February 2017 Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known
More informationRaymond James 38 th Annual Institutional Investor Conference. March 6, 2017
Raymond James 38 th Annual Institutional Investor Conference March 6, 2017 1 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation
More informationPhotocure ASA. Evolving into a Specialty Pharma company. Results for the fourth quarter and full year 2011
Brilliance in photodynamic technology Photocure ASA Evolving into a Specialty Pharma company Results for the fourth quarter and full year 2011 16 February 2012 Kjetil Hestdal, President & CEO Torbjørn
More informationSirtex Medical Limited Results for the full year ended 30 June 2017
Sirtex Medical Limited Results for the full year ended 30 June 2017 Andrew McLean CEO Darren Smith CFO Dr David N. Cade CMO 23 August 2017 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty
More informationINSTITUTIONAL RESEARCH Specialty Pharma COMPANY UPDATE Member FINRA/SIPC
INSTITUTIONAL RESEARCH Specialty Pharma COMPANY UPDATE Member FINRA/SIPC Toll Free: 561-391-5555 www.dawsonjames.com 1 North Federal Highway - Suite 500 Boca Raton, FL 33432 Pulmatrix (Nasdaq/PULM) BUY
More informationFor personal use only
ASX Code: A2M NZX Code: ATM 20 July 2015 NZX/ASX Market Release Record Australian earnings, Exceptional a2 Platinum infant formula growth, Positive progress in international markets With regard to recent
More information34 th Annual J.P. Morgan Healthcare Conference. Steve Collis, President & CEO Tim Guttman, EVP & CFO
34 th Annual J.P. Morgan Healthcare Conference Steve Collis, President & CEO Tim Guttman, EVP & CFO January 12, 2016 Steve Collis President & CEO Cautionary Note Regarding Forward-Looking Statements Certain
More informationAMAG Pharmaceuticals. November 2015 A SPECIALTY PHARMACEUTICAL COMPANY DEDICATED TO BRINGING TO MARKET THERAPIES THAT IMPROVE PATIENTS LIVES
Pharmaceuticals November 1100 Winter Street Waltham, MA 02451 617.498.3300 www.amagpharma.com A SPECIALTY PHARMACEUTICAL COMPANY DEDICATED TO BRINGING TO MARKET THERAPIES THAT IMPROVE PATIENTS LIVES All
More informationAkorn, Inc. N a s d a q : A K R X
Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global Healthcare Conference June 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect to our
More informationMayne Pharma (MYX) Yet Another Transformational Acquisition. FY16 Earnings Confirmed. The company did not provide guidance in respect of FY17.
29 June 2016 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Mayne Pharma (MYX) Merger Fallout Creates Opportunity Recommendation Buy (unchanged) Price $1.485 Target (12 months) $1.89
More informationOverview. Highlights. Financial highlights
Injectables Our Injectables business manufactures, markets and sells generic injectable products in the US, the MENA region and Europe. In the US, we are the third largest manufacturer of injectables by
More informationLannett Company, Inc. Kremers Urban Acquisition September 2, 2015
Lannett Company, Inc. Kremers Urban Acquisition September 2, 2015 Forward Looking Statements Except for historical facts, the statements in this presentation, as well as oral statements or other written
More informationLupin Investor Presentation Q3FY14
Lupin Investor Presentation Q3FY14 Vision: To be an innovation led transnational company Safe harbor statement Materials and information provided during this presentation may contain forward looking statements.
More informationAurobindo Pharma Limited. Presentation to Investors
Aurobindo Pharma Limited Presentation to Investors November 2013 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation,
More informationSigma Pharmaceuticals Limited
Investor Relations Contact: Gary Woodford Corporate Affairs Manager Gary.Woodford@signet.com.au Phone: 03 9215 9632 Mobile: 0417 399 204 Mark Hooper CEO and Managing Director Gary Woodford Corporate Affairs
More informationasx/media release ALS result up 18% as commodities recovery continues
asx/media release 20 November 2017 ALS result up 18% as commodities recovery continues H1FY18 Underlying NPAT 1 within guidance at $70.1 million Goodwill impairment charges of $63 million Asset Care business
More information30 MAY First quarter 2018 PRESENTED BY TOM RÖNNLUND, CEO Q1 2018
30 MAY 2018 First quarter 2018 PRESENTED BY TOM RÖNNLUND, CEO Q1 2018 Q1 Summary Navamedic reported revenues of NOK 42.6 million, compared to NOK 78.2 in Q1 2017 The Q1 2018 revenues decreased by 4.0 %
More informationLIFE STARTS HERE. FY18 Full Year Results Presentation. 27 August 2018
LIFE STARTS HERE FY18 Full Year Results Presentation 27 August 2018 Disclaimer The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) ( MVF ) (including its subsidiaries, affiliates
More informationThis information should be read in conjunction with Mayne Pharma Group Limited s 2012 Annual Report.
Manager, Company Announcements ASX Limited Level 4 20 Bridge Street SYDNEY, NSW 2000 Wednesday, 27 February 2013 Via E-Lodgement Dear Sir/Madam Mayne Pharma Group Limited Interim Results Please find attached
More informationFourth Quarter and Full Year 2017 Results. March 1, 2018
1 Fourth Quarter and Full Year 2017 Results March 1, 2018 Impax Cautionary Statement Regarding Forward Looking Statements 2 "Safe Harbor" statement under the Private Securities Litigation Reform Act of
More informationTeva Pharmaceuticals Industries Ltd. NASDAQ: TEVA. 12/2/18 Eric Abeles, Grant Kovel, Jared Robinson, Matthew Ross, Jacob Seidenberg
Teva Pharmaceuticals Industries Ltd. NASDAQ: TEVA 12/2/18 Eric Abeles, Grant Kovel, Jared Robinson, Matthew Ross, Jacob Seidenberg Table of Contents I. Security Overview II. Situational Overview III. Company
More informationQ4 & Full Year FY2018 Financial Results. November 6, 2018
Q4 & Full Year FY2018 Financial Results November 6, 2018 Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this presentation are forward-looking statements within
More informationCATALENT PHARMA SOLUTIONS, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationIR PRESENTATION January 2019
IR PRESENTATION January 2019 FORWARD-LOOKING STATEMENTS Certain information contained in these materials and to be discussed during this presentation constitute forward-looking information within the meaning
More informationCELLMID LIMITED NOTES TO THE APPENDIX 4C
ASX ANNOUNCEMENT CELLMID LIMITED NOTES TO THE APPENDIX 4C Highlights for the quarter ending 31 March 2018: Record receipts from customers of $2.2 million, an increase of 81% in Q3 FY2018 compared with
More informationChief Executive Officer
Said Darwazah Chief Executive Officer 211 highlights Strong Group performance in a challenging year 95 9 MSI PROMOPHARM $11.2 m $918.m 85 8 75 BRANDED + 9.6% $37.9 m INJECTABLES + 23.3% $36.7 m GENERICS
More information1H FY19 RESULTS PRESENTATION 25 February 2019
RELIANCE WORLDWIDE CORPORATION LIMITED ACN 610855877 1H FY19 RESULTS PRESENTATION 25 February 2019 INVESTOR PRESENTATION 1H FY19 RESULTS PAGE 0 Important Notice This presentation contains general information
More information2,033.8 Billions of yen Billions of cigarettes Billions of cigarettes Billions of yen 8.7 % 20.3 % 33, yen up 32.
Financial Highlights Japan Tobacco Inc. and Consolidated Subsidiaries / Fiscal year ended March 31, 2012 Business Scale JT Group Sales Volume Japanese Domestic Tobacco Business 108.4 Billions of cigarettes
More informationBrilliance in photodynamic technology TM. Establishing a Specialty Pharma company
Brilliance in photodynamic technology TM Establishing a Specialty Pharma company 28 April 2010 Results for the 1 st quarter 2010 Highlights for the first quarter 2010 (2009 figures in brackets) Hexvix
More informationInvestor Presentation
NZX Code: ATM ASX Code: A2M 3 May 2017 NZX/ASX Market Release Investor Presentation Please find attached a presentation to be given today by The a2 Milk Company Limited at Macquarie s annual Australia
More informationSummary of Financial Statements for the Three Month Period Ended June 30, 2017 (IFRS, Consolidated) July 28, 2017
Period Ended (IFRS, Consolidated) July 28, 2017 Takeda Pharmaceutical Company Limited Stock exchange listings: Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: http://www.takeda.co.jp Representative:
More informationAurobindo Pharma Limited Presentation to Investors
Aurobindo Pharma Limited Presentation to Investors February 2013 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation,
More informationThe world leader in photodynamic technology
Brilliance in photodynamic technology Results for the first quarter 2011 The world leader in photodynamic technology 27 April 2011 Highlights for the first quarter 2011 (Q1 2010 figures in brackets) Hexvix
More informationIntellipharmaceutics Announces First Quarter 2018 Results
April 16, 2018 Intellipharmaceutics Announces First Quarter 2018 Results TORONTO, ON / ACCESSWIRE / April 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics"
More informationIMPAX LABORATORIES INC
IMPAX LABORATORIES INC FORM 8-K (Current report filing) Filed 02/20/14 for the Period Ending 02/20/14 Address 30831 HUNTWOOD AVENUE HAYWARD, CA 94544 Telephone 510-240-6000 CIK 0001003642 Symbol IPXL SIC
More informationForward-Looking Statements. Consolidated Financial Results for the 3rd Quarter of Fiscal Year François-Xavier Roger Chief Financial Officer
Consolidated Financial Results for the 3rd Quarter of Fiscal Year 2014 François-Xavier Roger Chief Financial Officer February 5, 2015 Forward-Looking Statements This presentation contains forward-looking
More informationFor personal use only
Financial Results Half Year FY18 Ivan Slavich Chief Executive Officer Energy Action Limited Michael Fahey Chief Operating Officer & Chief Financial Officer Energy Action Limited Half Year FY18 Results
More informationBrilliance in photodynamic technology TM. - from Biotech to Specialty Pharma
Brilliance in photodynamic technology TM - from Biotech to Specialty Pharma 19 February 2010 Results for the 4 th quarter and full year 2009 Highlights for the fourth quarter 2009 (2008 figures in brackets)
More informationFor personal use only Y E A R R E S U L T S FY17
H A L F Y E A R R E S U L T S FY17 I M P O R T A N T N O T I C E & D I S C L A I M E R This presentation has been prepared by Specialty Fashion Group Limited (the Company ). It contains general background
More informationThank you, Cameron, for the introduction, and good morning. We are pleased to present Axsesstoday s FY18 end of year results, and FY19 guidance.
1300 586 936 ir@axsesstoday.com.au www.axsesstoday.com.au Level 9, 360 Collins Street Melbourne, Vic 3000, Australia ASX Announcement AXL FY18 Results Conference Call - Transcript Melbourne, 27 August
More informationFortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights New York, NY November 9, 2016 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company
More information26 November Company Announcements Office Australian Securities Exchange Limited Exchange Centre 20 Bridge Street Sydney NSW 2000
26 November 2013 Company Announcements Office Australian Securities Exchange Limited Exchange Centre 20 Bridge Street Sydney NSW 2000 Aristocrat Leisure Limited 2013 Aristocrat Leisure Limited will make
More informationSciClone Pharmaceuticals, Inc. (SCLN)
Company Update May 11, 2017 SciClone Pharmaceuticals, Inc. (SCLN) SciClone Pharmaceuticals Reports Strong Revenue Growth for First Quarter 2017 and Provides Corporate Update On May 10 th, SciClone Pharmaceuticals
More informationINSTITUTIONAL RESEARCH Specialty Pharma COMPANY UPATE Member FINRA/SIPC
INSTITUTIONAL RESEARCH Specialty Pharma COMPANY UPATE Member FINRA/SIPC Toll Free: 561-391-5555 www.dawsonjames.com 1 North Federal Highway - Suite 500 Boca Raton, FL 33432 Biofrontera (Nasdaq/BFRA) BUY
More informationIntellipharmaceutics Announces Second Quarter 2018 Results
July 16, 2018 Intellipharmaceutics Announces Second Quarter 2018 Results TORONTO, ON / ACCESSWIRE / July 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics"
More informationHalf Year Dublin, 26 July 2018
Half Year 2018 Dublin, 26 July 2018 Safe Harbour This presentation may include forward-looking statements that are based on our management s beliefs and assumptions and on information currently available
More informationInabox Group Limited (ASX:IAB)
Inabox Group Limited (ASX:IAB) AGM Presentation November 2016 A leading hosted IT and communications solution provider to Corporates, SME s and consumer brands across Australia. We invest in our people,
More informationLUPIN LIMITED. Q3 FY18 Investor Presentation. February 06, 2018
LUPIN LIMITED Q3 FY18 Investor Presentation February 06, 2018 Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements
More informationIR PRESENTATION June 2018
IR PRESENTATION June 2018 FORWARD-LOOKING STATEMENTS Certain information contained in these materials and to be discussed during this presentation constitute forward-looking information within the meaning
More informationSirtex Medical Limited
Sirtex Medical Limited Results for the half year ended 31st December 2016 Nigel Lange, Interim Group CEO Darren Smith, CFO Dr David N. Cade, CMO Kevin Richardson, CEO Americas Tony Dixon, CEO EMEA 22 February
More informationShaver Shop Group Limited 1H FY18 RESULTS INVESTOR PRESENTATION. 23 February 2018
Shaver Shop Group Limited 1H FY18 RESULTS INVESTOR PRESENTATION 23 February 2018 1 TABLE OF CONTENTS 01 Key business highlights 02 Financial results 03 Key growth drivers 04 Trading update& outlook 05
More informationQ4 and Full Year Results 2012
Q4 and Full Year Results 2012 Geoffrey McDonough (CEO) Alan Raffensperger (COO) Annika Muskantor (Interim CFO) Stockholm, 21 February 2013 Forward Looking Statements In order to utilize the Safe Harbor
More informationQ Earnings Conference Call
Q1 2018 Earnings Conference Call May 1, 2018 Christopher North, President and CEO Mike Pope, CFO Safe Harbor Disclaimer This presentation contains "forward-looking" statements within the meaning of Section
More informationShareholder Presentation. February 2016
Shareholder Presentation February 2016 DISCLAIMER This presentation has been prepared by BWX Limited ACN 169 015 838 (BWX) The information contained in this presentation is for information purposes only
More information31 st Annual J.P. Morgan Healthcare Conference JOHN CHIMINSKI PRESIDENT & CEO
31 st Annual J.P. Morgan Healthcare Conference JOHN CHIMINSKI PRESIDENT & CEO 01.08.2013 Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements
More informationCMIC HOLDINGS Co., Ltd. Consolidated Financial Results
(Note) This translation is prepared and provided for readers' convenience only. In the event of any discrepancy between this translated document and the original Japanese document, the original document
More informationBank of America Leveraged Finance Conference JOHN CHIMINSKI PRESIDENT & CEO
Bank of America Leveraged Finance Conference JOHN CHIMINSKI PRESIDENT & CEO Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements other than
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Investor Presentation May 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive
More information36 th Annual J.P. Morgan Healthcare Conference. January 8, 2018
36 th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements other than statements
More informationFY18 - Half Year Investor Presentation 22 February 2018
Who are we? FY18 - Half Year Investor Presentation 22 February 2018 Jonathan Rubinsztein CEO Richard Leon CFO Disclaimer Forward looking statements: All statements other than statements of historical fact
More informationASX Announcement FY2017 RESULTS
9.0 ASX Announcement 28 August, 2017 FY2017 RESULTS Net profit $7.0m Final dividend 2.5c, fully franked Composer contract secured with UK retail brand leader Major institutional bank s transition to Syn~
More informationSWK Holdings. May 2012
SWK Holdings May 2012 Forward-looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we believe or
More informationCMIC HOLDINGS Co., Ltd. Consolidated Financial Results
(Note) This translation is prepared and provided for readers' convenience only. In the event of any discrepancy between this translated document and the original Japanese document, the original document
More informationINSTITUTIONAL RESEARCH Specialty Pharma COMPANY UPDATE Member FINRA/SIPC
INSTITUTIONAL RESEARCH Specialty Pharma COMPANY UPDATE Member FINRA/SIPC Toll Free: 561-391-5555 www.dawsonjames.com 1 North Federal Highway - Suite 500 Boca Raton, FL 33432 Sonoma Pharmaceuticals (Nasdaq/SNOA)
More information